Hyperlipidemia
Conditions
Brief summary
This study will be conducted to assess the status of oxidative stress inflammation and thrombogenesis in patients with hyperlipidemia and to compare the antioxidative, anti-inflammatory and antithrombogenic effects of rosuvastatin and atorvastatin.
Detailed description
Hyperlipidemia is the major risk factor for development of atherosclerosis which ultimately leads to cardiovascular disease (CVD), an important cause of mortality and morbidity worldwide. Atherosclerosis was previously considered as a lipid storage disease but now growing evidence indicates that increased oxidative stress, vascular inflammation and platelet activation play an important role in the initiation and progression of atherosclerosis. Among the hypolipidemic drugs, statins, 3-hydroxyl-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, have proved to be very much effective. Therefore, statins are the most widely used hypolipidemic agents. Evidence shows that besides hypolipidemic action statins possess antioxidative, anti-inflammatory and antithrombogenic effects known as pleiotropic action which might play an important role in attenuating the atherosclerotic process. However, pleiotropic effect varies with different members of statins. The present prospective interventional study would be conducted in the Department of Pharmacology, Department of Cardiology and Internal Medicine, BSMMU from March 2016 to August 2017. Total 90 cases will be selected according to inclusion and exclusion criteria. The cases will be subdivided into 2 groups: group A and B. Group A consisting of 45 patients who will receive rosuvastatin (5-10) mg orally once daily and Group B consisting of 45 patients who will receive atorvastatin (10-20) mg orally once daily for 08 weeks. Patient's blood sample will be collected to measure baseline lipid profile, malondialdehyde (MDA), erythrocytic glutathione (GSH), high sensitive C-reactive protein (hs-CRP), prothrombin time (PT), platelet count. After obtaining baseline data patients will be assigned to the respective group. Parameters of baseline will again be evaluated after 08 weeks of therapeutic intervention. Regularity of drug intake will be ensured over telephone, pill count, and from the patient's compliance sheet. Patient's data will be recorded in a predetermined data sheet. Patients will be informed about study, its merits and demerits in easy language and then informed consent will be taken.Therefore, the present study has been designed to compare the antioxidative, anti-inflammatory and antithrombogenic effects of rosuvastatin and atorvastatin in hyperlipidemic patients to establish the superiority of a particular statin, so that it will provide a better therapeutic option in order to prevent CVD related mortality and morbidity.
Interventions
DRUGRosuvastatin
45 patients will be treated with rosuvastatin at a dose of (5-10) mg orally once daily dose for 08 weeks
DRUGAtorvastatin
45 patients will be treated with atorvastatin at a dose of (10-20) mg orally once daily dose for 08 weeks
Sponsors
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Age from (20-75) yrs, both male and female having LDL cholesterol: 160-190 mg/dl, triglyceride (TG): 200-499 mg/dl will be recruited in the study
Exclusion criteria
* Patients age \<25 years or \>75 years * Patients are on lipid lowering medications * Patients taking omega-3 fatty acid or garlic * Patients with history of hypersensitivity on any member of statin * Patients taking anti-inflammatory medications (steroid or NSAIDS) * Patients taking antioxidant vitamins (vitamin A, C, E) * Patients with impaired renal function * Patients with impaired liver function * Pregnant women and nursing mother * Patients having serious infections or terminal illness
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Establishment of superiority between rosuvastatin and atorvastatin on reduction of MDA in patients with hyperlipidemia | [0 weeks (baseline), 8 weeks (end)] [safety Issue: No] | Reduction of oxidative stress will be measured by changes in level of MDA in µmol/L |
| Establishment of superiority between rosuvastatin and atorvastatin on reduction of inflammation in patients with hyperlipidemia | [0 weeks (baseline), 8 weeks (end)] [safety Issue: No] | Reduction of inflammation will be measured by change in level of hs-CRP in mg/L |
| Establishment of superiority between rosuvastatin and atorvastatin on reduction platelet count in patients with hyperlipidemia | [0 weeks (baseline), 8 weeks (end)] [safety Issue: No] | Reduction of thrombogenesis will be measured by changes in level of platelet count in per L of blood |
| Establishment of superiority between rosuvastatin and atorvastatin on increase prothrombin time in patients with hyperlipidemia | [0 weeks (baseline), 8 weeks (end)] [safety Issue: No] | Reduction of thrombogenesis will be measured by changes in level of prothrombin time in per sec |
| Establishment of superiority between rosuvastatin and atorvastatin on increase level of erythrocytic GSH in patients with hyperlipidemia | [0 weeks (baseline), 8 weeks (end)] [safety Issue: No] | Reduction of oxidative stress will be measured by changes in level of erythrocytic GSH in mg/gm of Hb |
Countries
Bangladesh
Contacts
Primary ContactSamia Tonu, MBBS
Backup ContactNargis Akhter, Mphill, Msc
Outcome results
None listed